Isis, Biogen Ink Second Rare Disease Deal; Targeting DM1
Six months after signing an option agreement on a Phase I-stage antisense program in spinal muscular atrophy (SMA), Isis Pharmaceuticals Inc. and Biogen Idec Inc. agreed to a similarly structured deal for an earlier-stage rare disease program targeting myotonic dystrophy Type I (DM1), a muscular wasting disease also known as Steinert disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter